应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
LENZ Therapeutics
盘前交易 08-27 08:56:59 EDT
4.78
+0.11
+2.36%
盘前
4.85
+0.07
+1.46%
08:46 EDT
最高
4.84
最低
4.58
成交量
54.51万
今开
4.67
昨收
4.67
日振幅
5.57%
总市值
1.50亿
流通市值
8,792万
总股本
3,129万
成交额
259.22万
换手率
2.96%
流通股本
1,839万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Spyre Therapeutics股价下跌13.8%，因该公司试验药物未能达到类风湿性关节炎单药治疗开发的预设门槛。
智通财经 · 08-26 21:35
Spyre Therapeutics股价下跌13.8%，因该公司试验药物未能达到类风湿性关节炎单药治疗开发的预设门槛。
美股开盘 | 三大指数集体低开，Meta逆势涨超3%
老虎资讯综合 · 08-26 21:30
美股开盘 | 三大指数集体低开，Meta逆势涨超3%
Summit Therapeutics美股盘前涨超10%
智通财经 · 08-26 19:52
Summit Therapeutics美股盘前涨超10%
新闻稿：Oruka Therapeutics任命Todd Edwards为首席商务官
投资观察 · 08-25 04:04
新闻稿：Oruka Therapeutics任命Todd Edwards为首席商务官
据美国证券交易委员会披露文件显示，OS Therapeutics公司计划通过杰富瑞集团发售最高规模为7500万美元的普通
智通财经 · 08-22
据美国证券交易委员会披露文件显示，OS Therapeutics公司计划通过杰富瑞集团发售最高规模为7500万美元的普通
Lenz Therapeutics遭美银全球研究下调评级：从“买入”降至“中性”，目标价从31美元大幅下调至7美元
美股速递 · 08-13
Lenz Therapeutics遭美银全球研究下调评级：从“买入”降至“中性”，目标价从31美元大幅下调至7美元
Tenax Therapeutics股价暴跌87.2%，此前该公司的心脏药物在后期研究中未达到主要目标。
智通财经 · 08-10
Tenax Therapeutics股价暴跌87.2%，此前该公司的心脏药物在后期研究中未达到主要目标。
新闻稿：Ernexa Therapeutics 引入资深生物技术高管 David Polinsky 加入董事会，为临床阶段冲刺蓄力
投资观察 · 08-10
新闻稿：Ernexa Therapeutics 引入资深生物技术高管 David Polinsky 加入董事会，为临床阶段冲刺蓄力
Axsome Therapeutics（AXSM）二季度GAAP每股盈亏为0.99美元 营业收入2.184亿美元
金吾财讯 · 08-10
Axsome Therapeutics（AXSM）二季度GAAP每股盈亏为0.99美元 营业收入2.184亿美元
SIONNA Therapeutics 公布主要终点更新数据后，盘前股价暴跌 87%
智通财经 · 08-10
SIONNA Therapeutics 公布主要终点更新数据后，盘前股价暴跌 87%
Blossomhill Therapeutics Inc.美国IPO首日开盘报15.75美元，此前给出的IPO发行价为每
智通财经 · 08-08
Blossomhill Therapeutics Inc.美国IPO首日开盘报15.75美元，此前给出的IPO发行价为每
美股异动 | BlossomHill Therapeutics(BLSM.US)登陆美股市场 开盘后股价小幅走低
智通财经 · 08-08
美股异动 | BlossomHill Therapeutics(BLSM.US)登陆美股市场 开盘后股价小幅走低
新闻稿：Rani Therapeutics 任命 Michelle Gilson 加入董事会
投资观察 · 08-04
新闻稿：Rani Therapeutics 任命 Michelle Gilson 加入董事会
专注肿瘤领域的生物技术公司BlossomHill Therapeutics计划通过首次公开募股募资约1.328亿美元。
智通财经 · 08-04
专注肿瘤领域的生物技术公司BlossomHill Therapeutics计划通过首次公开募股募资约1.328亿美元。
生物科技公司Capricor Therapeutics面临FDA质疑与证券欺诈调查 股价连续暴跌
环球市场播报 · 07-28
生物科技公司Capricor Therapeutics面临FDA质疑与证券欺诈调查 股价连续暴跌
美股异动 | CRISPR基因编辑公司Scribe Therapeutics(SCTX.US)登陆美股市场 开盘后涨超59%
智通财经 · 07-24
美股异动 | CRISPR基因编辑公司Scribe Therapeutics(SCTX.US)登陆美股市场 开盘后涨超59%
Summit Therapeutics美股盘前跌超11%
每日经济新闻 · 07-22
Summit Therapeutics美股盘前跌超11%
小分子抗癌疗法开发商BlossomHill Therapeutics(BLSM.US)申请美股上市 拟筹资至多1亿美元
智通财经 · 07-20
小分子抗癌疗法开发商BlossomHill Therapeutics(BLSM.US)申请美股上市 拟筹资至多1亿美元
缺氧疗法生物科技公司NuvOx Therapeutics(NUOX.US)申请美股IPO，拟募资2000万美元
智通财经 · 07-20
缺氧疗法生物科技公司NuvOx Therapeutics(NUOX.US)申请美股IPO，拟募资2000万美元
新闻稿：Glucotrack与Lōkahi Therapeutics完成战略业务合并，建立Lōkahi控制的公开平台
投资观察 · 07-15
新闻稿：Glucotrack与Lōkahi Therapeutics完成战略业务合并，建立Lōkahi控制的公开平台
公司概况
公司名称：
Therapeutics
所属市场：
NASDAQ
上市日期：
--
主营业务：
LENZ Therapeutics, Inc.最初于2017年6月1日在加拿大安大略省注册成立，随后于2019年10月在特拉华州重新注册成立。该公司是一家商业制药公司，专注于开发和商业化改善视力的疗法，其主导产品VIZZ被批准用于治疗老花眼。
发行价格：
--
{"stockData":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":4.78,"timestamp":1787774400000,"preClose":4.67,"halted":0,"volume":545051,"hourTrading":{"tag":"盘前","latestPrice":4.85,"preClose":4.78,"latestTime":"08:46 EDT","volume":1972,"amount":9662.175862,"timestamp":1787834788411,"change":0.07,"changeRate":0.014644,"amplitude":0.042197},"delay":0,"changeRate":0.023554603854389792,"floatShares":18393300,"shares":31289969,"eps":-4.13,"marketStatus":"盘前交易","change":0.11,"latestTime":"08-27 08:56:59 EDT","open":4.67,"high":4.84,"low":4.58,"amount":2592171.8595136,"amplitude":0.055675,"askPrice":4.85,"askSize":109,"bidPrice":4.7,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-4.13,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787837400000},"marketStatusCode":1,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":4.78,"preHourTrading":{"tag":"盘前","latestPrice":4.85,"preClose":4.78,"latestTime":"08:46 EDT","volume":1972,"amount":9662.175862,"timestamp":1787834788411,"change":0.07,"changeRate":0.014644,"amplitude":0.042197},"postHourTrading":{"tag":"盘后","latestPrice":4.87,"preClose":4.78,"latestTime":"19:33 EDT","volume":3633,"amount":17401.86,"timestamp":1787787238297,"change":0.09,"changeRate":0.018828,"amplitude":0.037657},"volumeRatio":1.0238947081972003,"impliedVol":3.0968,"impliedVolPercentile":0.972},"requestUrl":"/m/hq/s/LENZ/wiki","defaultTab":"wiki","newsList":[{"id":"2662712415","title":"Spyre Therapeutics股价下跌13.8%，因该公司试验药物未能达到类风湿性关节炎单药治疗开发的预设门槛。","url":"https://stock-news.laohu8.com/highlight/detail?id=2662712415","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662712415?lang=zh_cn&edition=full","pubTime":"2026-08-26 21:35","pubTimestamp":1787751332,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LENZ","BK4539","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113424300","title":"美股开盘 | 三大指数集体低开，Meta逆势涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1113424300","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113424300?lang=zh_cn&edition=full","pubTime":"2026-08-26 21:30","pubTimestamp":1787751030,"startTime":"0","endTime":"0","summary":"8月26日，美股三大指数集体低开，道琼斯指数跌0.01%，标普500指数跌0.13%，纳斯达克综合指数跌0.22%。Meta涨超3%，与美国多个州同意就青少年社交媒体危害案达成和解；Summit Therapeutics涨超10%，核心候选药物依沃西单抗III期试验数据积极；爱芬奇涨超20%，Q2业绩超市场预期，同步上调全年业绩指引；先科电子涨超5%，Q2业绩远超市场预期，Q3业绩指引强劲。","market":"us","thumbnail":"https://static.tigerbbs.com/ff6e3231d788a5a6d28cf7965385cc7f","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/ff6e3231d788a5a6d28cf7965385cc7f"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0061474960.USD","LU2168564149.EUR","LU0234570918.USD","LU0276348264.USD","SG9999002224.SGD","LU1914381329.SGD","LU1301847155.USD","IE00B19Z8W00.USD","LU0053666078.USD","LU0724617625.USD","GXPC","SPUU","03086","LU2458330243.SGD","LU2361044865.SGD","LU2065171311.SGD","LU1564329461.SGD","LU0077335932.USD","LU2063271972.USD","DDM","TRUC","LU1551013342.USD","LU0417517546.SGD","YSPY","LU1066053197.SGD","LU1868837300.USD","SPXS","LU1868836591.USD","LU2404859741.USD","LU0133085943.USD","LU2756315318.SGD","DXD","LU2168564495.EUR","LU1868836914.USD","LU2602419157.SGD","LU2065171402.SGD","IE0009G5SDU7.USD","LU2023250330.USD","FBYY","LU0719512351.SGD","IE0005OL40V9.USD","LU0444971666.USD","LU1564329628.SGD","SG9999015952.SGD","IE00BQXX3F31.USD","LU0205194284.USD","FBY","LU0082616367.USD","IE0004445015.USD","LU2347655156.SGD","LU1861559042.SGD","LU2458330169.SGD","LU0006306889.USD","SMAX","IE0009356076.USD","MMAX","LU1674673428.USD","QLD","NOCT","HIBL","LU0345769631.USD","LU0823421333.USD","07261","IE00B1BXHZ80.USD","LU0170899867.USD","LU2764263203.CNY","LU1435385759.SGD","LU0683600562.USD","LU2065169927.USD","LU1917777945.USD","IE00B1XK9C88.USD","LU2106854487.HKD","IE00BJJMRY28.SGD","METU","OGIG","LU1791710400.SGD","LU1815336760.USD","LU2360106780.USD","LU0795875169.SGD","LU1732799900.SGD","IE00B5949003.HKD","02834","LU0256863811.USD","LU0096364046.USD","LU0661504455.SGD","SDS","BK4139","LU0265550359.USD","LU2272731865.HKD","SH","GB00BDT5M118.USD",".SPX","LU0912757837.SGD","LU1674673691.USD","LU2552382132.HKD","LU1791710582.SGD","METW","LU1059921491.USD","IE000W1ABFV2.USD","LU1035775433.USD","LU1720051108.HKD","SG9999015978.USD","FBX","LU2381873111.SGD","LU2023250843.SGD","IE00B775H168.HKD","SG9999014914.USD","XDAT","HK0000304805.HKD","LU0061474705.USD","DIA","LU1496350502.SGD","LU0323591593.USD","LU2133065610.SGD","SPYH","03455","FBL","BK4592","GPIQ","LU0354030438.USD","SGXZ81514606.USD","LU1697837992.HKD","LU2264538146.SGD","FCOM","LU0210528500.USD","IE0004445239.USD","07522","LU1153585028.USD","SG9999017495.SGD","SG9999018857.SGD","IE00BJLML261.HKD","LU1935042215.USD","LU0878866978.SGD","LU0552385451.USD","LU0985489474.SGD","LU1852331112.SGD","QID","SG9999015945.SGD","03034","LU0011850046.USD","LU0786609619.USD","LU2403377893.USD","LU2430703178.SGD","GB00B4LPDJ14.GBP","DMAX","LU0130102774.USD","LU2168564222.USD","BK4023","LU1935043536.SGD","LU0211328371.USD","UDOW","LU1988902786.USD","LU1145028129.USD","NDX","LU0320765489.SGD","LU0943347566.SGD","LU1201861249.SGD","LU0433182093.SGD","LU0354030511.USD","LU1084165304.USD","SG9999014898.SGD","LU1316542783.SGD","LU0949170426.SGD","LU0787776722.HKD","LU0642271901.SGD","LU1116320737.USD","IE00B19Z8X17.USD",".IXIC","BK4141","LU0187121727.USD","LU2764263039.SGD","SPYQ","LU1571399168.USD","LU1642822529.SGD","LENZ","LU0162691827.USD","LU1718418525.SGD","IE00BMPRXR70.SGD","LU0208291251.USD","LU1804176565.USD","BK4507","BK4094","LU0061475181.USD","LU2347655073.USD","LU0528227936.USD","LU2237957811.SGD","LU2236285917.USD","LU0203201768.USD","IE00BQXX3C00.GBP","LU1235294995.USD","LU2317271919.USD","LU0310799852.SGD","LU2552382058.USD","IE000SO60NU8.SGD","IE00BMPRXQ63.HKD","LU1935042488.USD","LU0149725797.USD","HK0000304797.USD","LU2125154778.USD","LU0466842654.USD","LU1868836757.USD","SPYM","LU1868837136.USD","LU2244417387.USD","LU1670711123.USD","LU0154236417.USD","LU2242650005.HKD","LU2322448957.HKD","TQQY","LU2168564065.EUR","IE00B19Z3581.USD","LU2430703251.USD","PSQ","IE0003U64NQ7.SGD","SDOW","LU1366192091.USD","SQQQ","LU1261432733.SGD","LU1559883803.SGD","LU0205193047.USD","LU1232071149.USD","META","SGXZ51526630.SGD","LU2168563687.JPY","LU1267930490.SGD","IE00BK4W5L77.USD","SPXL","LU1066051498.USD","09834","SOCL","LU0079474960.USD","IE00BKDWB100.SGD","LU0012050646.USD","HK0000914686.HKD","LU0823421416.USD","LU1116320901.HKD","LU0820562030.AUD","LU2237957902.USD","IE000KEQY171.SGD","LU0708995401.HKD","LU0820561818.USD","YMmain","LU1119994496.HKD","LU2430703095.HKD","LU1670711040.USD","LU0545039389.USD","LU0316494557.USD","LU0109391861.USD","LU2326559502.SGD","LU0072461881.USD","LU0234572021.USD","LU2322448791.USD","LU2463028550.USD","LU2023250504.SGD","LU0957808578.USD","SMMT","IE00BFSS8Q28.SGD","07568","LU0949170772.SGD","IE000YTNTUN2.SGD","LU2487616109.SGD","SPYU","SPXU","LU2054465674.USD","LU0109392836.USD","NJAN","LU0056508442.USD","SMTC","UPRO","LU0784383803.USD","LU0127658192.USD","LU0985320562.USD","LU1778281490.HKD","IE000ITXATA3.USD","LU1564329032.USD","LU2404859667.USD","LU0757428866.USD","LU0225283273.USD","HK0000914660.USD","IE00BQXX3D17.EUR","LU0267386448.USD","LU1429558221.USD","LU1974910355.USD","LU0211331839.USD","IE000WAW04H5.SGD","NJUL","METQ","LU2456880835.USD","SG9999014906.USD","LU1732800096.USD","LU1839511570.USD","IE0001KFT4U8.USD","IE00BJJMRX11.SGD","LU0738911758.USD","LU1979441026.SGD","IVV","IE00B7KXQ091.USD","LU1069344957.HKD","LU2417539215.USD","LU0314104364.USD","LU1046421795.USD","LU2361044949.HKD","LU0980610538.SGD","LU0345769128.USD","IE00BWXC8680.SGD","IE00BK4W5M84.HKD","SG9999001077.SGD","LU2720916845.USD","LU2097829019.USD","LU1003077747.HKD","IE00B7SZLL34.SGD","SG9999018865.SGD","IE00BFSS7M15.SGD","LU0784385170.HKD","LU1489326972.SGD","LU1823568750.SGD","LU0106261612.USD","LU1064131342.USD","LU1280957306.USD","SSO","IE00BN29S564.USD","LU1242518857.USD","LU2065170008.USD","IE00B4YYXB79.USD","IE000MB6IJN5.SGD","QTWO","LU2265009873.SGD","LU2756315664.SGD","LU0070302665.USD","LU0215105999.USD","SG9999004303.SGD","LU2272731782.SGD","LU1720051017.SGD","LU1127390331.HKD","SMETAmain","ANF","TQQQ","GAMR","LU0096362180.USD","LU2896262040.SGD","LU1699723380.USD","LU0689472784.USD","IE00BJTD4V19.USD","LU2746668461.USD","LU0964807845.USD","LU0979878070.USD","LU2357305700.SGD","LU0690374961.EUR","SGXZ23171101.USD","RSPC","LU1815333072.USD","IE0002270589.USD","LU0690374615.EUR","IE0034235303.USD","LU2462157665.USD","BK4587","IE00B4JS1V06.HKD","SGXZ80539844.SGD","LU2505996681.GBP","LU0444973449.USD","LU1551013425.SGD","BK4585","SMTG","LU2087621335.USD","LU2543165471.USD","LU1548497426.USD","METV","LU2488822045.USD","LU2360032135.SGD","SG9999015986.USD","IE000BZT7R73.USD","LU0068578508.USD","LU0265550946.USD","LU0553294199.USD","BK4007","LU2746668974.SGD","METG","NULC","LU0256863902.USD","LU0476273544.USD","NAPR","LU1670627923.USD","LU0320765059.SGD","LU2125154935.USD","LU0784384876.USD","QQQ","LU1935042991.SGD","LU0823434740.USD","LU1242518931.SGD","LU0784385840.USD","LU0211327993.USD","LU1814569148.SGD","LU2361045086.USD","SGXZ31699556.SGD","LU1074936037.SGD","SPDN","LU1629891620.HKD","LU0640476718.USD","LU1267930730.SGD","LU0353189680.USD","IE00B19Z9505.USD","LU1670710661.SGD","GB00B4QBRK32.GBP","LU2272731600.USD","LU1935043023.USD","LU0672654240.SGD","IE000F7OJYX1.SGD","LU0889565833.HKD","BK4539","LU2247934214.USD","LU0203347892.USD","07266","SG9999002232.USD","LU0210536198.USD","LU0566484027.USD","LU0726765562.USD","LU1803068979.SGD","LU0072462426.USD","LU2087625088.SGD","LU0198837287.USD","LU0157215616.USD","LU1815336091.USD","IE00B19Z3B42.SGD","LTL","LU1366333091.USD","IE0000B7K699.USD","LU0648001328.SGD","LU0203345920.USD","IE00BJTD4N35.SGD","LU0795875086.SGD","LU1861558580.USD","LU1992135399.USD","LU0957791311.USD","LU2505996509.AUD","QDEC","BK4543","LU1670710588.SGD","LU2860962120.EUR","LU2420271590.USD","LU2462591350.SGD","VOO","LU0203202063.USD","LU0308772762.SGD","LU2461242641.AUD","IE00B3SWFQ91.USD","LU0823434583.USD","SG9999014880.SGD",".DJI","LU0820561909.HKD","LU0080751232.USD","LU2473716301.USD","QMAR","DOG","SPY","LU2250418816.HKD","LU0788109477.HKD","LU1564329115.USD","BK4077","LU1670628061.USD","LU0106261372.USD","LU0210533765.USD","LU2592432038.USD","QQQM","LU0070217475.USD","LU0353189763.USD","XLC","LU0097036916.USD","09086","LU1992135472.HKD","LU2552382215.SGD","VOX","QQQX","LU2213496289.HKD","BK4588","IE0034235188.USD","LU0174119429.USD","LU2764262908.HKD","IE00BMPRXN33.USD","BK4524","METD","SGXZ99366536.SGD","LU0882574139.USD","LU0348723411.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662716390","title":"Summit Therapeutics美股盘前涨超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662716390","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662716390?lang=zh_cn&edition=full","pubTime":"2026-08-26 19:52","pubTimestamp":1787745128,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LENZ","BK4539","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185070568","title":"新闻稿：Oruka Therapeutics任命Todd Edwards为首席商务官","url":"https://stock-news.laohu8.com/highlight/detail?id=1185070568","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185070568?lang=zh_cn&edition=full","pubTime":"2026-08-25 04:04","pubTimestamp":1787601874,"startTime":"0","endTime":"0","summary":"加州门洛帕克，2026年8月24日——Oruka Therapeutics, Inc.是一家临床阶段的生物技术公司，致力于开发新型生物制剂，旨在为斑块状银屑病和化脓性汗腺炎等慢性皮肤病的治疗树立新标准。该公司今日宣布，任命Todd Edwards为首席商务官，自2026年8月24日起生效。他此前在Arcutis Biotherapeutics, Inc.担任执行副总裁兼首席商务官，期间领导了ZORYVE产品线的转型——重建了银屑病商业组织，推出了特应性皮炎和脂溢性皮炎的新适应症，并实现了持续的收入增长。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORKA","LENZ","BK4022","LU0889565916.HKD","LU0320765992.SGD","BK4232","BK4007","R","BK4139","BK4539","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661290857","title":"据美国证券交易委员会披露文件显示，OS Therapeutics公司计划通过杰富瑞集团发售最高规模为7500万美元的普通","url":"https://stock-news.laohu8.com/highlight/detail?id=2661290857","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661290857?lang=zh_cn&edition=full","pubTime":"2026-08-22 04:43","pubTimestamp":1787345036,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","BK4539","BK4127","JEF","LENZ","BK4007","BK4559","SOLC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164486796","title":"Lenz Therapeutics遭美银全球研究下调评级：从“买入”降至“中性”，目标价从31美元大幅下调至7美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1164486796","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164486796?lang=zh_cn&edition=full","pubTime":"2026-08-13 19:10","pubTimestamp":1786619414,"startTime":"0","endTime":"0","summary":"美银全球研究机构近日对Lenz Therapeutics作出了关键性调整。该机构将这家公司的股票评级从“买入”直接下调至“中性”。这并非孤立的举措，同一时间，它们还彻底修正了其价格预期，目标价已从先前的31美元大幅削减至7美元，降幅十分显著。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4139","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658931704","title":"Tenax Therapeutics股价暴跌87.2%，此前该公司的心脏药物在后期研究中未达到主要目标。","url":"https://stock-news.laohu8.com/highlight/detail?id=2658931704","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658931704?lang=zh_cn&edition=full","pubTime":"2026-08-10 21:31","pubTimestamp":1786368718,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","BK4007","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193258586","title":"新闻稿：Ernexa Therapeutics 引入资深生物技术高管 David Polinsky 加入董事会，为临床阶段冲刺蓄力","url":"https://stock-news.laohu8.com/highlight/detail?id=1193258586","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193258586?lang=zh_cn&edition=full","pubTime":"2026-08-10 21:09","pubTimestamp":1786367399,"startTime":"0","endTime":"0","summary":"此次任命正值公司关键转折点，进一步强化了其领导团队——Ernexa 正全力推进其核心项目 ERNA-101，计划于2026年第三季度提交新药临床试验申请，并在第四季度启动首项一期临床研究。马萨诸塞州剑桥市，2026年8月10日——Ernexa Therapeutics，一家致力于开发创新细胞疗法以治疗晚期癌症和自身免疫性疾病的行业先锋，今日宣布任命 David Polinsky 为其董事会成员。“我们正步入 Ernexa 历史上最为重要的时期之一，”Ernexa Therapeutics 总裁兼首席执行官 Sanjeev Luther 表示。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYNB","ERNA","LENZ","BK4205","IND","XBI","BBP","IBB","BK4539","RFL","BK4233","BK4588","BK4007","BK4581","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658933459","title":"Axsome Therapeutics（AXSM）二季度GAAP每股盈亏为0.99美元 营业收入2.184亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2658933459","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658933459?lang=zh_cn&edition=full","pubTime":"2026-08-10 19:27","pubTimestamp":1786361253,"startTime":"0","endTime":"0","summary":"金吾财讯 | Axsome Therapeutics 公布第二季度财务数据，公司GAAP每股盈亏为0.99美元，较市场预期低0.10美元。当期实现营业收入2.184亿美元，同比增幅达到45.6%，但较市场一致预期少338万美元。该企业专注于中枢神经系统领域药物开发与商业化，本季度营收大幅上涨，主要来源于已上市药物的市场销售放量。不过销售、研发等多项运营开支同步走高，最终造成每股亏损不及预期。","market":"us","thumbnail":"https://static.szfiu.com/news/20210625/YzM5OTgzZmE3NTA3Njg3Nzc4Mjg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/YzM5OTgzZmE3NTA3Njg3Nzc4Mjg=.jpg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"303617","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UUP","LENZ","UDN","AXSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658938295","title":"SIONNA Therapeutics 公布主要终点更新数据后，盘前股价暴跌 87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658938295","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658938295?lang=zh_cn&edition=full","pubTime":"2026-08-10 19:13","pubTimestamp":1786360392,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","BK4539","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657640905","title":"Blossomhill Therapeutics Inc.美国IPO首日开盘报15.75美元，此前给出的IPO发行价为每","url":"https://stock-news.laohu8.com/highlight/detail?id=2657640905","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657640905?lang=zh_cn&edition=full","pubTime":"2026-08-08 00:33","pubTimestamp":1786120437,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LENZ","BK4127","FRHC","KCE","BK4139","REDS","IPOS","BK4539","UUP","UDN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657640472","title":"美股异动 | BlossomHill Therapeutics(BLSM.US)登陆美股市场 开盘后股价小幅走低","url":"https://stock-news.laohu8.com/highlight/detail?id=2657640472","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657640472?lang=zh_cn&edition=full","pubTime":"2026-08-08 00:00","pubTimestamp":1786118400,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周五，BlossomHill Therapeutics登陆美股市场，截至发稿，该股跌超1%，报15.8美元。BlossomHill Therapeutics总部位于加州圣地亚哥，成立于2020年。该公司专注于通过识别现有治疗方法中的结构性弱点，并设计新的化合物来克服这些弱点，从而开发小分子癌症药物。公司计划于2026年第四季度与美国食品药品监督管理局举行一期临床结束会议，讨论推荐的二期临床给药方案，以及针对部分患者潜在的加速批准路径。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477624.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LENZ","BLSM","BK4539","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193281325","title":"新闻稿：Rani Therapeutics 任命 Michelle Gilson 加入董事会","url":"https://stock-news.laohu8.com/highlight/detail?id=1193281325","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193281325?lang=zh_cn&edition=full","pubTime":"2026-08-04 20:12","pubTimestamp":1785845578,"startTime":"0","endTime":"0","summary":"加利福尼亚州圣何塞，2026年8月4日——专注于口服生物制剂递送的临床阶段生物治疗公司 Rani Therapeutics Holdings, Inc.今日宣布，任命 Michelle Gilson 为其董事会成员。Gilson 女士将担任审计委员会主席。“Michelle 兼具深厚的资本市场专业知识和在高增长生物技术公司担任财务领导的实际经验，这使她成为我们董事会的一位卓越新成员，”Rani Therapeutics 首席执行官 Talat Imran 表示。“能在公司如此关键的时期加入 Rani Therapeutics 董事会，我深感荣幸，”Michelle Gilson 说道。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","BK4007","LENZ","BK4022","BK4232","R"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656303576","title":"专注肿瘤领域的生物技术公司BlossomHill Therapeutics计划通过首次公开募股募资约1.328亿美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2656303576","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656303576?lang=zh_cn&edition=full","pubTime":"2026-08-04 00:41","pubTimestamp":1785775260,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4539","BK4139","ACSG","HELX","LQPE","BK4007","SPCK","LENZ","BCSM","QQQS","PEVC","IPO","WDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654885615","title":"生物科技公司Capricor Therapeutics面临FDA质疑与证券欺诈调查 股价连续暴跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2654885615","media":"环球市场播报","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654885615?lang=zh_cn&edition=full","pubTime":"2026-07-28 23:15","pubTimestamp":1785251700,"startTime":"0","endTime":"0","summary":"生物科技公司Capricor Therapeutics正面临严峻挑战，其股价近期大幅下挫——周一该股收盘重挫64.49%，周二早盘再跌逾15%。FDA审查人员对Capricor的核心候选药物deramiocel的疗效数据提出质疑，认为其关键性III期HOPE-3试验未能达到预设的主要和关键次要疗效终点。此外，多家律师事务所已对Capricor提起或正在调查证券欺诈集体诉讼。诉讼主要指控公司在2024年10月9日至2025年7月10日期间，就其获得FDA批准的可能性作出了虚假和误导性陈述，同时隐瞒了关于deramiocel安全性和有效性的不利事实。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-07-28/doc-inikksxz1845469.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["161027","IBBJ","BK4007","LNGR","IEIH","LENZ","SYNB","BK4588","159837","GDOC","BK4585","XBI","AGNG","LABU","HBImain","MEDX","BK4539","BK4139","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654036699","title":"美股异动 | CRISPR基因编辑公司Scribe Therapeutics(SCTX.US)登陆美股市场 开盘后涨超59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2654036699","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654036699?lang=zh_cn&edition=full","pubTime":"2026-07-24 23:57","pubTimestamp":1784908651,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4007","HELX","FWD","LU1861558580.USD","SYNB","LU1861559042.SGD","CRSP","ARKG","XT","BK4611","BK4556","BK4139","LENZ","IDNA","NBDS","BK4539","GNOM","KOMP","TARK","DTEC","SCTX","BK4585","BK4588","BMED","WDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653751229","title":"Summit Therapeutics美股盘前跌超11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653751229","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653751229?lang=zh_cn&edition=full","pubTime":"2026-07-22 18:36","pubTimestamp":1784716593,"startTime":"0","endTime":"0","summary":"Summit Therapeutics美股盘前跌超11%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607223817433621.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607223817433621.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LENZ","BK4139","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652298740","title":"小分子抗癌疗法开发商BlossomHill Therapeutics(BLSM.US)申请美股上市 拟筹资至多1亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2652298740","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652298740?lang=zh_cn&edition=full","pubTime":"2026-07-20 15:20","pubTimestamp":1784532012,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，BlossomHill Therapeutics是一家管线已推进至二期临床阶段的生物技术企业，专注于开发小分子抗癌疗法。该公司于上周五向美国证券交易委员会递交招股书，拟通过首次公开募股募资至多1亿美元。BlossomHill Therapeutics专注研发小分子抗癌药物：先找出现有疗法的结构缺陷，再设计新的化合物来克服这些缺陷。BlossomHill Therapeutics于2026年4月24日秘密提交了上市申请。摩根大通、Leerink Partners、Guggenheim Securities、LifeSci Capital和HC Wainwright是此次交易的联合承销商。定价条款未披露。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469696.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4539","IPOS","BK4139","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652298685","title":"缺氧疗法生物科技公司NuvOx Therapeutics(NUOX.US)申请美股IPO，拟募资2000万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2652298685","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652298685?lang=zh_cn&edition=full","pubTime":"2026-07-20 14:55","pubTimestamp":1784530507,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4588","KCE","BK4127","IPOS","AGNG","BK4581","MEDX","BK4539","SYNB","FRHC","BK4585","XBI","LENZ","BK4007","BK4139","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182696709","title":"新闻稿：Glucotrack与Lōkahi Therapeutics完成战略业务合并，建立Lōkahi控制的公开平台","url":"https://stock-news.laohu8.com/highlight/detail?id=1182696709","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182696709?lang=zh_cn&edition=full","pubTime":"2026-07-15 05:45","pubTimestamp":1784065528,"startTime":"0","endTime":"0","summary":"Glucotrack, Inc.今日宣布，其与Lōkahi Therapeutics的战略业务合并已正式完成。本次交易的结构设计使得Lōkahi Therapeutics成为合并后公司的运营及控制主体，并利用Glucotrack的公开市场平台来支持长期增长及资本获取。在交易完成之际，Lōkahi Therapeutics的证券持有人获得了Glucotrack普通股与可转换优先股的组合。届时，在完全稀释基础上，并受交易相关融资及常规调整影响，Lōkahi Therapeutics的证券持有人将持有合并后公司约90%的股份。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GCTK","BK4139","BK4007","BK4082","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://ir.lenz-tx.com","stockEarnings":[{"period":"1week","weight":-0.0285},{"period":"1month","weight":-0.1614},{"period":"3month","weight":-0.4018},{"period":"6month","weight":-0.6457},{"period":"1year","weight":-0.8763},{"period":"ytd","weight":-0.7012}],"compareEarnings":[{"period":"1week","weight":-0.0039},{"period":"1month","weight":0.0365},{"period":"3month","weight":0.0152},{"period":"6month","weight":0.1168},{"period":"1year","weight":0.1874},{"period":"ytd","weight":0.1234}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"LENZ Therapeutics, Inc.最初于2017年6月1日在加拿大安大略省注册成立，随后于2019年10月在特拉华州重新注册成立。该公司是一家商业制药公司，专注于开发和商业化改善视力的疗法，其主导产品VIZZ被批准用于治疗老花眼。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.137955},{"month":2,"riseRate":0.4,"avgChangeRate":0.032476},{"month":3,"riseRate":0.2,"avgChangeRate":-0.143415},{"month":4,"riseRate":0.4,"avgChangeRate":-0.0217},{"month":5,"riseRate":0.2,"avgChangeRate":-0.134259},{"month":6,"riseRate":0.6,"avgChangeRate":-0.009929},{"month":7,"riseRate":0.5,"avgChangeRate":0.033083},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.002572},{"month":9,"riseRate":0.6,"avgChangeRate":0.026875},{"month":10,"riseRate":0.6,"avgChangeRate":-0.067546},{"month":11,"riseRate":0.6,"avgChangeRate":-0.005451},{"month":12,"riseRate":0.4,"avgChangeRate":-0.038411}],"exchange":"NASDAQ","name":"Therapeutics","nameEN":"Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Therapeutics(LENZ)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Therapeutics(LENZ)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Therapeutics,LENZ,Therapeutics股票,Therapeutics股票老虎,Therapeutics股票老虎国际,Therapeutics行情,Therapeutics股票行情,Therapeutics股价,Therapeutics股市,Therapeutics股票价格,Therapeutics股票交易,Therapeutics股票购买,Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Therapeutics(LENZ)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Therapeutics(LENZ)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}